Reference priceEUR €577.50Original source price: INR 52,500.00. Converted estimates are available by currency selection.
| Brand | Novantrone |
|---|---|
| Manufacturer | Lederle Laboratories |
| Prescription required | Yes |
Novantrone 25mg/ml 12.5ml(mitoxantrone)
MITOXANTRONE
Description
Novantrone 25mg/ml 12.5ml(mitoxantrone) is a medicine catalog record in the MediPriceHub database. Active ingredient: MITOXANTRONE. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: Lederle Laboratories. Therapeutic category: Medicine Library > Oncology Medicines > Liver Cancer Medicines. Pack information: 25 / 12.5. Origin country or market: United States. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.Benefits
Mitoxantrone injection, USP (concentrate) is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). Mitoxantrone injection, USP (concentrate) is not indicated in the treatment of patients with primary progressive multiple sclerosis. The clinical patterns of multiple sclerosis in the studies were characterized as follows: secondary progressive and progressive relapsing disease were characterized by gradual increasing disability with or without superimposed clinical relapses, and worsening relapsing-remitting disease was characterized by clinical relapses resulting in a step-wise worsening of disability. Mitoxantrone injection, USP (concentrate) in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. Mitoxantrone injection, USP (concentrate) in combination with other approved drug(s) is indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias.How to Use
Use MITOXANTRONE under the supervision of a qualified healthcare professional. Use it only according to the approved label and the instructions of a qualified healthcare professional. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.Specification
Active ingredient: MITOXANTRONE. Pack size: 25 / 12.5. Pack unit: bottle. Manufacturer: Lederle Laboratories. Origin country: United States. Source category: Medicine Library > Oncology Medicines > Liver Cancer Medicines. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.Side Effects
What are the ingredients in Novantrone? How does Novantrone work? What are the possible side effects of Novantrone? Many clinical trials eva luated the safety and efficacy of Novantrone. The most common side effects experienced by those taking Novantrone include: If you have trouble breathing, experience swelling of legs or ankles, or uneven or fast heartbeat, call 911 immediately. These problems generally happen in people who receive a lifetime dose of more than 12 doses but can also occur at lower lifetime doses. Novantrone may reduce white blood cell count, which increases the chance of getting an infection. It may also cause your platelet count to go down, which increases the chance of bleeding; this is why regular blood tests are conducted. Call the doctor if you experience fever, chills, sore throat, cough, pain with urination, urination more often, or if you notice any unusual bleeding or bruising. Things to note about Novantrone Patients with MS may experience changes in cardiac function when treated with Novantrone. Before initiating therapy everyone should have a cardiac assessment including taking a history, physical examination, ECG, and quantitative LVEF (Left ventricular ejection fraction) eva luation. People with a baseline LVEF below the lower limit of normal should not be treated with Novantrone. A complete blood count including platelets, and liver function tests, should be obtained prior to each course of Novantrone, and if signs of infection develop. Novantrone and its metabolites are excreted in the bile and urine. It may cause a blue-green color to the whites of your eyes (sclera) and the urine for 24 hours after administration. Before starting Novantrone, talk with your doctor if you have: This is not an exhaustive list of all potential side effects of Novantrone. For more information, consult your doctor or healthcare provider. If you notice any new or worsening side effects when taking Novantrone, contact your doctor or healthcare provider immediately. Dosing Informatio Novantrone is supplied to medical facilities as a concentrate and must be diluted prior to injection. The recommended dosage of Novantrone is 12 mg/m2 given and should be given slowly into a freely flowing IV infusion every 3 months. Cumulative lifetime dose should not exceed 140 mg/m2. For additional details, read the full prescribing information of Novantrone.Diese Angaben dienen nur als Referenz. Lassen Sie sich vor der Anwendung eines Medikaments von medizinischem Fachpersonal beraten.